Tim A. Kanters

1.0k total citations
43 papers, 675 citations indexed

About

Tim A. Kanters is a scholar working on Economics and Econometrics, Pediatrics, Perinatology and Child Health and Physiology. According to data from OpenAlex, Tim A. Kanters has authored 43 papers receiving a total of 675 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Economics and Econometrics, 12 papers in Pediatrics, Perinatology and Child Health and 11 papers in Physiology. Recurrent topics in Tim A. Kanters's work include Health Systems, Economic Evaluations, Quality of Life (18 papers), Lysosomal Storage Disorders Research (10 papers) and Pharmaceutical studies and practices (8 papers). Tim A. Kanters is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (18 papers), Lysosomal Storage Disorders Research (10 papers) and Pharmaceutical studies and practices (8 papers). Tim A. Kanters collaborates with scholars based in Netherlands, United Kingdom and Australia. Tim A. Kanters's co-authors include Leona Hakkaart‐van Roijen, Clazien Bouwmans, Naomi van der Linden, Siok Swan Tan, Ans T. van der Ploeg, Ken Redekop, Maureen Rutten‐van Mölken, Michelle E. Kruijshaar, Werner Brouwer and Adri Steenhoek and has published in prestigious journals such as PLoS ONE, Neurology and Social Science & Medicine.

In The Last Decade

Tim A. Kanters

42 papers receiving 664 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tim A. Kanters Netherlands 17 202 141 96 96 94 43 675
Krista Payne United States 14 85 0.4× 75 0.5× 107 1.1× 106 1.1× 66 0.7× 21 893
David Phillippo United Kingdom 16 221 1.1× 150 1.1× 66 0.7× 42 0.4× 68 0.7× 29 1.1k
Masayo Sato Japan 17 52 0.3× 76 0.5× 111 1.2× 114 1.2× 133 1.4× 70 958
Xiaoyun Pan United States 14 128 0.6× 75 0.5× 40 0.4× 38 0.4× 100 1.1× 41 671
Pierluigi Russo Italy 20 280 1.4× 50 0.4× 119 1.2× 32 0.3× 131 1.4× 89 1.2k
K Malottki United Kingdom 11 124 0.6× 52 0.4× 43 0.4× 78 0.8× 166 1.8× 17 725
Hüseyin Yüce United States 21 110 0.5× 63 0.4× 78 0.8× 77 0.8× 87 0.9× 87 1.1k
Pranav Gandhi United States 13 54 0.3× 90 0.6× 73 0.8× 114 1.2× 40 0.4× 56 515
Ashutosh Gupta India 16 149 0.7× 75 0.5× 246 2.6× 24 0.3× 98 1.0× 48 850
Shonda A. Foster United States 18 86 0.4× 74 0.5× 52 0.5× 158 1.6× 197 2.1× 41 782

Countries citing papers authored by Tim A. Kanters

Since Specialization
Citations

This map shows the geographic impact of Tim A. Kanters's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tim A. Kanters with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tim A. Kanters more than expected).

Fields of papers citing papers by Tim A. Kanters

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tim A. Kanters. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tim A. Kanters. The network helps show where Tim A. Kanters may publish in the future.

Co-authorship network of co-authors of Tim A. Kanters

This figure shows the co-authorship network connecting the top 25 collaborators of Tim A. Kanters. A scholar is included among the top collaborators of Tim A. Kanters based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tim A. Kanters. Tim A. Kanters is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Groot, Saskia de, Tim A. Kanters, Louis Wagner, et al.. (2024). Effectiveness of Seizure Dogs for People With Severe Refractory Epilepsy. Neurology. 102(6). e209178–e209178. 1 indexed citations
2.
Fijen, Lauré M., et al.. (2023). The Disease Burden and Societal Costs of Hereditary Angioedema. The Journal of Allergy and Clinical Immunology In Practice. 11(8). 2468–2475.e2. 7 indexed citations
3.
Groot, Saskia de, Tim A. Kanters, Matthijs Versteegh, et al.. (2022). Burden of illness in people with medically refractory epilepsy who suffer from daily to weekly seizures: 12-month follow-up of participants in the EPISODE study. Frontiers in Neurology. 13. 1012486–1012486. 10 indexed citations
4.
Huygens, Simone, et al.. (2022). Costs of Persons with Dementia Living in Nursing Homes in The Netherlands. Journal of Alzheimer s Disease. 89(1). 359–366. 2 indexed citations
5.
Sajjad, Ayesha, et al.. (2021). Productivity of Working at Home and Time Allocation Between Paid Work, Unpaid Work and Leisure Activities During a Pandemic. PharmacoEconomics. 40(1). 77–90. 16 indexed citations
6.
Groot, Saskia de, Matthijs Versteegh, Tim A. Kanters, et al.. (2021). Good Days and Bad Days: Measuring Health-Related Quality of Life in People With Epilepsy. Value in Health. 24(10). 1470–1475. 6 indexed citations
7.
Huygens, Simone, et al.. (2021). Methodological Challenges in the Economic Evaluation of a Gene Therapy for RPE65-Mediated Inherited Retinal Disease: The Value of Vision. PharmacoEconomics. 39(4). 383–397. 14 indexed citations
8.
Franken, M, Tim A. Kanters, J.L. Coenen, et al.. (2019). PCN330 A COMPARISON OF HEALTHCARE AND SOCIETAL COSTS OF HOSPITAL-BASED AND HOME-BASED SUBCUTANEOUS INJECTIONS OF TRASTUZUMAB. Value in Health. 22. S500–S500. 1 indexed citations
9.
Franken, M, Tim A. Kanters, Jules L.L.M. Coenen, et al.. (2018). Potential cost savings owing to the route of administration of oncology drugs. Anti-Cancer Drugs. 29(8). 791–801. 30 indexed citations
10.
Mulders‐Manders, Catharina M., Tim A. Kanters, Paul Van Daele, et al.. (2018). Decreased quality of life and societal impact of cryopyrin-associated periodic syndrome treated with canakinumab: a questionnaire based cohort study. Orphanet Journal of Rare Diseases. 13(1). 59–59. 11 indexed citations
11.
Kanters, Tim A., Ans T. van der Ploeg, Michelle E. Kruijshaar, et al.. (2017). Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in adult patients with Pompe disease. Orphanet Journal of Rare Diseases. 12(1). 179–179. 17 indexed citations
12.
13.
Kanters, Tim A., Ken Redekop, Maureen Rutten‐van Mölken, et al.. (2015). A conceptual disease model for adult Pompe disease. Orphanet Journal of Rare Diseases. 10(1). 112–112. 9 indexed citations
14.
Güngör, Deniz, Michelle E. Kruijshaar, Iris Plug, et al.. (2015). Quality of Life and Participation in the Daily Life (Activities) of Adults with Pompe Disease Receiving Enzyme Replacement Therapy: 10 Years of International Follow-Up. Journal of Neuromuscular Diseases. 2(s1). S63–S63. 1 indexed citations
15.
Kanters, Tim A., Leona Hakkaart‐van Roijen, Maureen Rutten‐van Mölken, & Ken Redekop. (2015). Access to orphan drugs in western Europe: can more systematic policymaking really help to avoid different decisions about the same drug?. Expert Review of Pharmacoeconomics & Outcomes Research. 15(4). 557–559. 14 indexed citations
16.
Kanters, Tim A., Adri Steenhoek, & Leona Hakkaart‐van Roijen. (2014). Budget Impact of Orphan Drugs In the Netherlands In The Period 2006-2012. Value in Health. 17(7). A525–A525. 2 indexed citations
17.
Kanters, Tim A., Adri Steenhoek, & Leona Hakkaart‐van Roijen. (2014). Orphan drugs expenditure in the Netherlands in the period 2006–2012. Orphanet Journal of Rare Diseases. 9(1). 154–154. 24 indexed citations
18.
Kanters, Tim A., Ken Redekop, Michelle E. Kruijshaar, et al.. (2014). Comparison of EQ-5D and SF-6D utilities in Pompe disease. Quality of Life Research. 24(4). 837–844. 13 indexed citations
19.
Kanters, Tim A., et al.. (2013). Systematic review of available evidence on 11 high-priced inpatient orphan drugs. Orphanet Journal of Rare Diseases. 8(1). 124–124. 21 indexed citations
20.
Kanters, Tim A., Ken Redekop, & Leona Hakkaart‐van Roijen. (2012). PHP111 Factors Predicting Reimbursement Decisions on Orphan Drugs in Eight Countries. Value in Health. 15(7). A308–A308. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Krista Payne Breakdown of academic impact, for papers by David Phillippo Breakdown of academic impact, for papers by Masayo Sato Breakdown of academic impact, for papers by Xiaoyun Pan Breakdown of academic impact, for papers by Pierluigi Russo Breakdown of academic impact, for papers by K Malottki Breakdown of academic impact, for papers by Hüseyin Yüce Breakdown of academic impact, for papers by Pranav Gandhi Breakdown of academic impact, for papers by Ashutosh Gupta Breakdown of academic impact, for papers by Shonda A. Foster
Rankless by CCL
2026